BASF Intensifies Restructuring Amid Challenging Market Outlook

BASF expands cost-saving target to €2.3B annually by 2026 as it forecasts EBITDA below analyst consensus. The firm continues portfolio restructuring and share buybacks.

The German chemical giant BASF is accelerating its corporate transformation, marked by a significant expansion of its cost-saving initiatives. This strategic push comes as the company navigates a persistently difficult operating environment and provides financial targets for 2026 that have fallen short of market expectations.

Financial Targets Disappoint, Cost Cuts Deepen

Market sentiment was dampened by BASF's operational outlook for 2026. The company forecasts EBITDA before special items to land between €6.2 billion and €7.0 billion. The midpoint of this range, €6.6 billion, sits notably below the approximate €7.0 billion consensus estimate among analysts. CEO Markus Kamieth offered a cautious perspective, stating that from today's viewpoint, the company does not anticipate a significant market recovery or a clear easing of geopolitical tensions in the near term.

In response, the savings program is being substantially widened. BASF now aims to achieve an annual run-rate for cost savings of €2.3 billion by the end of 2026, a sharp increase from the €1.7 billion target set for the end of 2025. The conglomerate estimates cumulative one-time costs to reach these savings at €1.9 billion. The workforce has already been reduced by 4,800 employees, with plans to shift additional administrative functions to India.

Portfolio Reshaping Continues Apace

The company's structural portfolio overhaul is gaining momentum. Two key moves illustrate this strategy. Firstly, BASF finalized the sale of its optical brightening agents business, including production in Monthey, Switzerland, to Catexel in late February. Approximately 80 employees transferred to the Care Chemicals platform of the International Chemical Investors Group. Financial terms of the transaction were not disclosed.

Secondly, the agricultural solutions division is being prepared for a stock market listing by 2027. Furthermore, the divestment of the coatings business is expected to be completed in the second quarter of 2026. These actions contribute to an improved balance sheet, with net debt declining to €18.33 billion, a figure CFO Dirk Elvermann noted represents 3.2 times net debt to adjusted EBITDA.

Capital Allocation: Buybacks, Capped Capex, and Stable Dividends

BASF's capital allocation strategy remains active. Between February 23 and 27, the company repurchased 673,113 of its own shares via the Xetra trading system. This is part of an ongoing program covering up to €1.5 billion through the end of June 2026, itself a component of a larger €4 billion minimum buyback plan extending to 2028. The repurchases are being financed through proceeds from portfolio divestments.

Simultaneously, the company is tightening its capital expenditure. Planned investments in property, plant, and equipment for the period from 2026 to 2029 have been set at €13 billion, which is 20% lower than originally intended. For shareholders, the dividend for 2025 is projected to remain stable at €2.25 per share. Free cash flow for the year is anticipated to be between €1.5 billion and €2.3 billion.

Operational Headwinds Persist

The first quarter of 2025 is proving particularly challenging. Outside of China, volumes in January were weak, and the company faces an additional currency headwind of up to €200 million. Performance is expected to vary by segment: while Nutrition & Care and Chemicals are forecast to deliver significant growth, the Materials and Agricultural Solutions divisions are likely to report currency-driven declines.

The full-year 2024 results, while supported by a special income of roughly €1.3 billion from government guarantees related to former Russia activities, highlighted underlying pressures. Operationally, EBITDA before special items declined by 9.5% to €6.554 billion. Group sales receded by 2.9% to €59.657 billion.

Investors reacted cautiously to the updates, with BASF shares declining by three percent last Friday. The coming months will reveal whether the combined strategy of portfolio streamlining, aggressive cost reduction, and restrained investment can successfully counteract the current operational weaknesses.